The market for CVD Prevention is expected to grow at a CAGR of around 5.8% from 2020 to 2027 and expected to reach the market value of around US$ 258.4 Bn by 2027.
Cardiovascular disease or CVD prevention can be reached by practicing a balanced healthy diet, regular exercise, avoiding smoking, and by the maintenance of optimal blood pressure (BP) and normal LDL-cholesterol and glucose levels. CVD covers a range of different diseases and conditions that affects the heart and/or blood vessels. The most important risk factor of CVD is hypertension and dyslipidemia which accelerates the development of atherosclerotic within blood vessels. Moreover, the treatment of CVD focuses on prevention by controlling the above-mentioned risk factors. The prevention encompasses Anti-hypertensives aims to lower blood pressure, anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range, and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of current thrombi. Along with these, the use of regular monitoring devices is recommended for the prevention of the persons who are at the risk of CVD.
Market Dynamics
The rapidly increasing cases of cardiovascular disease (CVD) across the globe are the alarm that the need for prevention has occurred and the necessary solutions are awaited in the market. According to the World Health Organization (WHO), CVD is responsible for 17 million deaths every year worldwide, which is approximately 31% of total deaths, and expects that this figure will rise to over 23 million by 2030. Additionally, the major economic burden of CVD also favors the growth of the CVD prevention market. For instance, the annual cost of CVD to the economy is estimated to range between £19-35 billion in the UK and over US$500 billion in the US including the cost of health care services, medicines, and loss of productivity due to death. The high prevalence of high blood pressure, high cholesterol, and smoking across the globe are further bolstering the risk of developing CVD. Moreover, the men were more likely than women to have at least one of the three CVD risk factors. Furthermore, ongoing R&D activities and technological advancement are projected to provide potential opportunities over the forecast timeframe from 2020 to 2027.
On the other side, the less frequency of detection and diagnosis of the relevant risk factors due to unawareness among people is likely to restrict the growth to an extent over the estimated period from 2020 to 2027.
North America leading the CVD Prevention market with maximum revenue share
In 2019, North America was leading the global CVD Prevention market with maximum revenue share (%) on account of its increasing geriatric population coupled with the escalating number of CVD patients. According to the U.S. Department of Health & Human Services, around 655,000 Americans die from heart disease every year which is equal to 1 in every 4 deaths. Moreover, Asia Pacific is projected to exhibit the fastest growth with major CAGR (%) throughout the forecast period from 2020 to 2027. The economic development and raising awareness about CVD prevention in the region is supporting the regional market growth.
The players profiled in the report include AstraZeneca plc, Boehringer Ingelheim GmbH, MyoKardia, Novartis, Roche Holding AG., Sanofi S.A., Takeda Pharmaceutical Company Limited, United Therapeutics Corporation, and others. The major CVD prevention players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the CVD prevention market for technological advancements in the field.
Market Segmentation
Market By Product Types
Detection & Diagnosis
- Artificial intelligence in cardiovascular imaging
- In vitro diagnostics at point-of-care
Remote Patient Monitoring
- Wearable technology for remote patient monitoring
- Non-wearable technology for remote patient monitoring
Treatment
- Anti-Hypertensives
- Anti-Dyslipidemia Drugs
- Anti-Thrombotic Drugs
Market By End User
Hospital
Home Health Care
Ambulatory Care
Speciality Clinics
Others
Market By Geography
North America
Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Chapter 1. Industry Overview of CVD Prevention
1.1 Definition and Scope
1.1.1 Definition of CVD Prevention
1.1.2 Market Segmentation
1.1.3 Years Considered for the Study
1.1.4 Assumptions and Acronyms Used
1.1.4.1 Market Assumptions and Market Forecast
1.1.4.2 Acronyms Used In Global CVD Prevention Market
1.2 Summary
1.2.1 Executive Summery
1.2.2 CVD Prevention Market By Product Type
1.2.3 Global CVD Prevention Market By Application
1.2.4 Global CVD Prevention Market by Regions
Chapter 2. Research Approach
2.1 Methodology
2.1.1 Research Programs/By Resolution Type
2.1.2 Market Size Estimation
2.1.3 Market Breakdown and Data Triangulation
2.2 Data Source
2.2.1 Secondary Sources
2.2.2 Primary Sources
Chapter 3. Market Dynamics and Competition Analysis
3.1 Market Drivers
3.1.1 Driver 1
3.1.2 Driver 2
3.2 Restraints and Challenges
3.2.1 Restraint 1
3.2.2 Restraint 2
3.3 Growth Opportunities
3.3.1 Opportunity 1
3.3.2 Opportunity 2
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitute
3.4.4 Threat of New Entrants
3.4.5 Degree of Competition
3.5 Market Concentration Ratio And Market Maturity Analysis of CVD Prevention Market
3.5.1 Go To Market Strategy
3.5.1.1 Introduction
3.5.1.2 Growth
3.5.1.3 Maturity
3.5.1.4 Saturation
3.5.1.5 Possible Development
3.6 Technological Roadmap for CVD Prevention Market
3.7 Value Chain Analysis
3.7.1 List of Key Manufacturers
3.7.2 List of Customers
3.7.3 Level of Integration
3.8 Regulatory Compliance
3.9 Competitive Landscape, 2019
3.9.1 Player Positioning Analysis
3.9.2 Key Strategies Adopted By Leading Players
Chapter 4. CVD Prevention Market By Product Type
4.1 Introduction
4.2 Global CVD Prevention Revenue (US$ Mn) by Product Type
4.2.1 Global CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 – 2027
4.2.2 DETECTION & DIAGNOSIS
4.2.2.1 DETECTION & DIAGNOSIS Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.2.1.1 Artificial intelligence in cardiovascular imaging
4.2.2.1.1.1 Artificial intelligence in cardiovascular imaging Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.2.1.2 In vitro diagnostics at point-of-care
4.2.2.1.2.1 In vitro diagnostics at point-of-care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3 REMOTE PATIENT MONITORING
4.2.3.1 REMOTE PATIENT MONITORING Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3.1.1 Wearable technology for remote patient monitoring
4.2.3.1.1.1 Wearable technology for remote patient monitoring Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3.1.2 Non-wearable technology for remote patient monitoring
4.2.3.1.2.1 Non-wearable technology for remote patient monitoring Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4 TREATMENT
4.2.4.1 TREATMENT Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.1 Anti-hypertensives
4.2.4.1.1.1 Anti-hypertensives Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.2 Anti -dyslipidemia drugs
4.2.4.1.2.1 Anti-dyslipidemia drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.3 Anti-thrombotic drugs
4.2.4.1.3.1 Anti-thrombotic drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.3 Market Attractive Analysis By Product Type 2019
Chapter 5. CVD Prevention Market By Application
5.1 Introduction
5.2 Global CVD Prevention Revenue (US$ Mn) by Application
5.2.1 Global CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
5.2.2 Hospital
5.2.2.1 Hospital Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.3 Home Health Care
5.2.3.1 Home Health Care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.4 Ambulatory Care
5.2.4.1 Ambulatory Care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.5 Speciality Clinics
5.2.5.1 Speciality Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.6 Others
5.2.6.1 Others Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.3 Market Attractive Analysis By Application 2019
Chapter 6. North America CVD Prevention Market By Country
6.1 North America CVD Prevention Market Overview
6.2 U.S.
6.2.1 U.S. CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
6.2.2 U.S. CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
6.3 Canada
6.3.1 Canada CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
6.3.2 Canada CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
6.4 North America PEST Analysis
Chapter 7. Europe CVD Prevention Market By Country
7.1 Europe CVD Prevention Market Key Overview
7.2 UK
7.2.1 UK CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.2.2 UK CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.3 Germany
7.3.1 Germany CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.3.2 Germany CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.4 France
7.4.1 France CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.4.2 France CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.5 Spain
7.5.1 Spain CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.5.2 Spain CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.6 Rest of Europe
7.6.1 Rest of Europe CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.6.2 Rest of Europe CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.7 Europe PEST Analysis
Chapter 8. Asia-Pacific CVD Prevention Market By Country
8.1 Asia Pacific CVD Prevention Market Overview
8.2 China
8.2.1 China CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.2.2 China CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.3 Japan
8.3.1 Japan CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.3.2 Japan CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.4 India
8.4.1 India CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.4.2 India CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.5 Australia
8.5.1 Australia CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.5.2 Australia CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.6 South Korea
8.6.1 South Korea CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.6.2 South Korea CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.7 Rest of Asia-Pacific
8.7.1 Rest of Asia Pacific CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.7.2 Rest of Asia Pacific CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.8 Asia Pacific PEST Analysis
Chapter 9. Latin America CVD Prevention Market By Country
9.1 Latin America CVD Prevention Market Overview
9.2 Brazil
9.2.1 Brazil CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.2.2 Brazil CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.3 Mexico
9.3.1 Mexico CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.3.2 Mexico CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.4 Rest of Latin America
9.4.1 Rest of Latin America CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.4.2 Rest of Latin America CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.5 Latin America PEST Analysis
Chapter 10. Middle East & Africa CVD Prevention Market By Country
10.1 Middle East & Africa CVD Prevention Market Overview
10.2 Saudi Arabia
10.2.1 Saudi Arabia CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.2.2 Saudi Arabia CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.3 UAE
10.3.1 UAE CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.3.2 UAE CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.4 Rest of Middle East & Africa
10.4.1 Rest of Middle East & Africa CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.4.2 Rest of Middle East & Africa CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.5 Middle East & Africa PEST Analysis
Chapter 11. Player Analysis of CVD Prevention
11.1 Global CVD Prevention Market Company Share Analysis
11.2 Competition Matrix
11.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2 New Product Launches and Product Enhancements
11.2.3 Mergers And Acquisition In Global CVD Prevention Market
11.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
Chapter 12. Company Profile
12.1 AstraZeneca plc
12.1.1 Company Snapshot
12.1.2 Business Overview
12.1.3 Financial Overview
12.1.3.1 Revenue (US$ Mn), 2019
12.1.3.2 AstraZeneca plc 2019 CVD Prevention Business Regional Distribution
12.1.4 Product/Service and Specifications
12.1.5 Recent Development & Business Strategy
12.1.6 Manufacturing Plant Footprint Analysis
12.2 Boehringer Ingelheim GmbH
12.3 MyoKardia
12.4 Novartis
12.5 Roche Holding AG.
12.6 Sanofi S.A.
12.7 Takeda Pharmaceutical Company Limited
12.8 United Therapeutics Corporation
12.9 Others
![CVD Prevention Market (By Product Types: Detection & Diagnosis [Artificial intelligence in cardiovascular imaging, In vitro diagnostics at point-of-care], Remote Patient Monitoring [Wearable technology for remote patient monitoring, Non-wearable technology for remote patient monitoring], Treatment [Anti-Hypertensives, Anti-Dyslipidemia Drugs, Anti-Thrombotic Drugs]; By End User: Hospital, Home Health Care, Ambulatory Care, Speciality Clinics, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2020 - 2027](assets/images/format-png.png "CVD Prevention Market (By Product Types: Detection & Diagnosis [Artificial intelligence in cardiovascular imaging, In vitro diagnostics at point-of-care], Remote Patient Monitoring [Wearable technology for remote patient monitoring, Non-wearable technology for remote patient monitoring], Treatment [Anti-Hypertensives, Anti-Dyslipidemia Drugs, Anti-Thrombotic Drugs]; By End User: Hospital, Home Health Care, Ambulatory Care, Speciality Clinics, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2020 - 2027")
